Cancer Research

Powerful multianalyte liquid biopsy analysis

Multianalyte liquid biopsy research

Have you ever asked yourself: Do we miss (or even waste) genomic and transcriptomic information by considering only one liquid biopsy analyte? How would the picture change if all analytes could be investigated?

Puzzled about which analyte to study in liquid biopsies for cancer research?

You can get a complete picture from liquid biopsies by stabilizing and isolating multiple analytes from the same blood draw to generate robust and reproducible insights.

It might be easier than you think to start isolating circulating  tumor cells (CTCs), cell-free DNA (cfDNA) and circulating RNAs from blood samples. And you don’t have to do it all at once. Storage of samples until you are ready to analyze them increases your flexibility to plan your studies and accelerate your research.

Watch videos and download resources

Multianalyte mentoring
Are you planning your multianalyte study and would benefit from mentoring? Share your details and we will contact you.
Apply here

Learn more about the ELIMA multianalyte studies

cfDNA variants and matched CTC gDNA variants: Is it possible and worth analyzing both?

Corinna Keup, Ph.D., University Hospital of Essen, Germany

Liquid biopsy analytes such as cell-free DNA (cfDNA) and circulating tumor cells (CTCs) exhibit great potential for personalized treatment. Since cfDNA and CTCs are considered to give additive information and blood specimens are limited, analysis of cfDNA and CTC in an “all from one tube” format is desired. Corinna presents a targeted DNA-seq workflow for CTC gDNA and cfDNA evaluation from the same blood sample and elucidates the value of cfDNA and CTC variants by comparing variants.

CTCs and their value in multimodality liquid biopsies analysis

Siegfried Hauch, QIAGEN

Circulating tumor cells, cell-free DNA (cfDNA) and extracellular vesicles – what can we learn when analyzing all of these from one blood sample? Discuss with Siegfried the value of multimodality liquid biopsy testing and the findings from a condensed workflow for multiple analyte extraction and analysis from one blood sample.

Listen to the Science talk with Sabine Kasimir-Bauer, University Hospital Essen, joined by Siegfried Hauch, Constanze Kindler and Markus Sprenger-Haussels
Molecular analysis research of circulating tumor cells, extracellular vesicles and nucleic acids in liquid biopsies

The use of biological fluids such as blood as a non-invasive source of cellular and nucleic acid biomarkers would be an ideal "surrogate tissue" to identify and monitor prognostic and predictive factors that will help in selecting the optimal therapeutic strategy for each individual patient. Sabine Kasimir-Bauer and her team approached this challenge and compared and analyzed, all from one blood sample, RNA profiles enclosed in circulating tumor cells or extracellular vesicles and performed mutational analysis of cell-free DNA (cfDNA) in plasma samples (next-generation sequencing) in the follow up of the disease to get insights into their feasibility for therapy stratification and to predict therapeutic options.

mRNA profiling of matched CTCs and EVs: an example for synergy

The analysis of RNA enclosed in circulating tumor cells (CTCs) or extracellular vesicles (EVs) may be sensitive enough to detect disease progression earlier than contemporary visual staging methods. Corinna Keup talks about her research study, comparing RNA profiles of CTCs and extracellular vesicles (EVs) in metastatic breast cancer (MBC) patients to get insights about their feasibility for therapy stratification.

Corinna Keup, University Hospital Essen, joined by Siegfried Hauch, Constanze Kindler and Martin Schlumpberger 
Corinna Keup joined by Siegfried Hauch and Markus Storbeck

ccfDNA targeted deep sequencing: new insights into clinical relevance of liquid biopsies

Cell-free DNA (cfDNA) is described to mirror intra-tumoral heterogeneity and gives insights about clonal evolution for improved therapeutic decisions. Corinna Keup discusses targeted deep sequencing of cfDNA of a hormone receptorpositive, HER2-negative metastatic breast cancer (MBC) cohort to examine the prevalence and relevance of variants and dynamics under treatment. Unique molecular identifiers enable the identification of true positive mutations in cfDNA.

Our speakers

Let’s work to conquer cancer. Together.